Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 6, 2006 Brian Lawler	Cephalon on the Hunt The biopharma company is looking to make more acquisitions and gets some good news from the FDA. Cephalon's stock climbed by more than 10% after the announcement.
The Motley Fool September 26, 2006 Brian Lawler	A Savior for Cephalon? The FDA's approval of Fentora comes just in time for the drug company. Investors, take note.
The Motley Fool August 19, 2004 Charly Travers	1 Pill for Sleep, Attention Ailments? Cephalon gets some good news about its drug PROVIGIL.
The Motley Fool March 24, 2006 Brian Gorman	Cephalon Takes a Hit The FDA rules against its ADHD drug, but Cephalon's current lineup still holds promise. Investors may want to look at the current sell-off as a potential buying opportunity.
The Motley Fool April 2, 2007 Brian Lawler	FDA Keeps Cephalon Waiting The FDA issues Cephalon an approvable letter for one of its drugs. Investors, take note.
The Motley Fool November 22, 2006 Brian Lawler	How to Market a Drug Too Well Cephalon's promotion of its pain drug Actiq might have crossed the line.
The Motley Fool November 6, 2006 Brian Lawler	No Worries About Cephalon This solid biopharma ups its yearly guidance -- for the fourth time. Investors, take note.
BusinessWeek November 1, 2004 Amy Barrett	This Pep Pill is Pushing Its Luck Half of Provigil prescriptions may be for "off-label" uses. Did its maker cross the line? But Cephalon is hardly the only drugmaker in the spotlight.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool November 4, 2004 Charly Travers	Drug Growth Screeching to a Halt Given the threat of generics to not-so-small drug company Cephalon's product line, the acquisition of CIMA labs in August of this year could turn out to be quite important.
The Motley Fool March 30, 2010 Brian Orelli	FDA Lags, Investors Flee Cephalon gets no love from the FDA. The agency failed to expand Cephalon's Nuvigil for the treatment of jet lag.
The Motley Fool February 16, 2007 Brian Lawler	Cephalon's Supercharged Growth The pharmaceutical announces fourth-quarter results and updates 2007 guidance. Investors, take note.
The Motley Fool June 27, 2005 Brian Gorman	Alkermes' Powerful Partnership Alkermes recently agreed to partner with Cephalon to commercialize Alkermes' Vivitrex, an experimental drug to treat alcoholism. The deal should bring strong sales and valuable experience.
The Motley Fool February 14, 2008 Brian Lawler	Waking Cephalon Up Specialty pharma Cephalon presents its 2007 financial results and 2008 guidance.
The Motley Fool August 3, 2007 Brian Lawler	Cephalon's Case of Spending Blues Cephalon announces its second-quarter financial results. Sales were up, so why is the share price down? Perhaps escalating SG&A expenses are the culprit.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
BusinessWeek April 24, 2006 Arlene Weintraub	Eyes Wide Open Cephalon's careful marketing of its narcolepsy drug could serve as a manual for turning new ideas into hit products.
The Motley Fool April 16, 2008 Brian Lawler	Cephalon Convinces the Continent The pharmaceutical's lead pain drug gets approved for marketing in Europe.
The Motley Fool July 27, 2010 Jim Mueller	3 Stocks to Play Biotech Here are three promising ideas for this exciting area.
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
The Motley Fool February 17, 2006 Brian Gorman	Enthusiasm for Cephalon The company seems to be counting on a strong showing for a new drug, but for investors, it may pay to be cautious.
The Motley Fool November 9, 2007 Brian Lawler	Cephalon Wheels and Deals Sales and net income fall in the third quarter, but increased guidance sends shares of the drugmaker higher.
The Motley Fool September 8, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool April 27, 2007 Brian Lawler	Cephalon's Earnings Surprise The drugmaker raises its earnings guidance for the year. With no serious competition for its lead compounds in the near term, investors should take a look at the well-run pharma.
The Motley Fool December 31, 2007 Brian Lawler	Cephalon's Date With the FDA In the last day of the year, Cephalon announces that it has submitted another New Drug Application for oncology treatment Treanda. Expect to hear back from FDA on this priority review before the middle of 2008.
Pharmaceutical Executive March 1, 2007 Walter Armstrong	He's Just Being Frank Cephalon's Frank Baldino is going global with plans to corner cancer.
The Motley Fool April 11, 2011 Jim Mueller	A Missed Opportunity Cephalon showed up on my screen as a potential buy, but others liked it, too.
The Motley Fool October 13, 2010 Brian Orelli	Don't Get Addicted to Alkermes' Low Revenue Vivitrol's launch and the approval of Bydureon will drive revenue -- and Alkmeres' stock price -- in the future.
Chemistry World May 4, 2011 Andrew Turley	Teva sidelines Valeant with $6.8bn Cephalon bid US drugmaker Cephalon has agreed to a $6.8 billion ( 4.1 billion) takeover bid from Israeli generics manufacturer Teva, which has beaten into second place Canadian pharma company Valeant.
The Motley Fool May 7, 2008 Brian Lawler	Cephalon's Long Shot Falls Short An FDA advisory panel brings bad news for the company.
The Motley Fool May 3, 2011 Brian Orelli	Teva's Branded-Drug Binge For a company that's a generic-drug maker, Teva Pharmaceuticals sure does like its branded drugs. Despite the warts the company is ponying up $6.2 billion to buy Cephalon.
The Motley Fool January 28, 2010 Brian Orelli	How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward.
The Motley Fool August 24, 2009 Brian Orelli	J&J Would Rather Not Say Drug delayed, reason unknown. Should shareholders be worried? It's hard to tell.
The Motley Fool September 14, 2010 Luke Timmerman	Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug.
The Motley Fool September 14, 2007 Brian Lawler	"Dear Doctor" Letter Spells Trouble for Cephalon Cephalon sends a letter to health-care practitioners warning of the dangers of misusing one of its lead drugs, Fentora. Investors, take note.
The Motley Fool March 31, 2011 Brian Orelli	Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good.
The Motley Fool April 1, 2008 Brian Lawler	Cephalon Plays "Let's Make a Deal" Cephalon acquires an oncology drug on the cheap from tiny Acusphere.
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
The Motley Fool December 29, 2006 Brian Lawler	No Pain for Alexza December's been good to lots of pharmas, but Alexza in particular has something to thank Santa for. Investors should pay close attention when Alexza issues its AZ-001 trial results next year.
BusinessWeek July 2, 2007 Arlene Weintraub	Lifestyle Drug Binge The huge profits in weight-loss and other treatments makes them hard for drugmakers to resist. But safety risks abound.
The Motley Fool July 6, 2007 Brian Lawler	Another Round for Alkermes' Alcohol Fight Alkermes advances the development of another drug. Investors, take note.
The Motley Fool December 27, 2006 Brian Lawler	Alkermes' Japanese Opportunity With Japan commanding over 10% of global pharmaceutical sales and Risperdal sales gaining ground, there will be big bucks for Alkermes if Risperdal can gain marketing approval over there.
BusinessWeek April 24, 2006 Arlene Weintraub	A Cephalon Vet Takes On Insomnia Jack Lief helped create Provigil, the elixir of wakefulness. But his startup is committed to helping people sleep.
The Motley Fool December 9, 2009 Brian Orelli	Rising From the ASHes At the Super Bowl of blood cancer, the American Society of Hematology's annual conference, the presentations by drug companies made a few stocks catch on fire, while a couple burned up a little.
The Motley Fool May 20, 2010 Brian Orelli	FDA Transparency! A Big Win for Investors The Food and Drug Administration has possibly just made things easier for investors. Let's just hope drug companies don't shoot it down.
The Motley Fool September 27, 2007 Brian Lawler	FDA Repeats Itself With Cephalon's Fentora In the wake of a letter from Cephalon to health-care practitioners, the FDA has issued a press release and a public health advisory of the dangers of misusing the company's pain drug Fentora. Investors, take note.
BusinessWeek June 24, 2010 Bliss & Decker	Ending the Silence of Generic Drugmakers The FTC says drugmakers are paying generic rivals not to compete.
The Motley Fool August 27, 2007 Brian Lawler	Cephalon Makes A Deal The newest drug in its cabinet is expected to hit the U.S. market in the fourth quarter. Investors will know relatively soon whether Cephalon pulled off another coup or just flushed $100 million down the toilet.
The Motley Fool January 31, 2011 Brian Orelli	Time to Buy Into Stem Cells? New developments bring this analyst a step closer to opening his wallet.
ifeminists May 24, 2006 Gerald K. McOscar	ADHD Is it child abuse per se for parents to allow doctors to prescribe mind altering drugs with potentially serious or fatal psychiatric side effects to their children, no matter how challenged...or challenging?